Vienna, Austria, March 23, 2026 – The Society of Laboratory Automation and Screening (SLAS) has unveiled the next wave of transformative innovation with the announcement of the 12 pioneering companies selected for its prestigious Innovation AveNEW program at the upcoming SLAS Europe 2026 Conference and Exhibition. This highly anticipated event, set to unfold from May 19 to 21 in Vienna, Austria, highlights SLAS’s unwavering commitment to fostering cutting-edge advancements within the life sciences discovery and technology domains. Serving as a vital nexus for startups, Innovation AveNEW amplifies the visibility of emerging ventures, bridging them with the vast global scientific community dedicated to revolutionizing laboratory automation and screening methods.
Innovation AveNEW represents more than just an exhibition platform; it functions as a strategic launchpad for nascent companies eager to introduce groundbreaking technologies, products, and services to an influential, multinational audience of purchasing decision-makers and scientific experts spanning over 40 countries. The program’s comprehensive support structure is distinguished by SLAS’s financial sponsorship, which includes coverage of exhibition fees, travel, and lodging for a primary company representative. Beyond the logistical facilitation, participants benefit from bespoke business consulting, mentorship, and enhanced promotional avenues—ensuring both visibility and viability in a competitive marketplace. A significant feature of the program is the opportunity for selected entities to publish their scientific manuscripts in SLAS’s esteemed peer-reviewed journals, SLAS Discovery and SLAS Technology, both of which are open-access and published by Elsevier.
The selection process for Innovation AveNEW is a stringent evaluation conducted by an expert panel who assesses applicants primarily on technical excellence and commercial promise. The criteria encompass a spectrum of attributes, including scientific innovation, startup status authenticity, leadership prowess, clear strategic vision, market potential, and tangible impact on laboratory automation and technological progress. This rigorous scrutiny ensures that only companies with the greatest potential to influence and advance the field are showcased. Moreover, every selected company gains eligibility to compete for the coveted SLAS Ignite Award, a prestigious accolade accompanied by a €5,000 prize. The forthcoming SLAS Europe 2026 conference will reveal the award winner, further elevating the recognition and momentum for the winning enterprise.
This year’s cohort of Innovation AveNEW companies is a testament to the global dispersion of innovation and entrepreneurship. Among the new startups are Germany’s 8-BOT Robotics, known for pioneering automation robotics tailored for laboratory workflows; the USA-based Chemetrian, which specializes in advanced chemical informatics platforms; Australia’s Culturon® Pty Ltd, offering revolutionary cell culture technologies; and the UK’s DaltonTX, innovators in precision laboratory instruments. The list continues with The Ensynble, Inc. from the USA, which develops integration solutions for lab automation; Germany’s linkdlab GmbH focusing on smart lab connectivity; Lutèce Dynamics from France, creators of dynamic assay platforms with real-time analytics; and the UK’s PartitionBio Ltd, dedicated to disease-focused biotechnology. Complements to this group include Scalables (USA), delivering scalable bioinformatics tools; Sync Biosystems (Netherlands), pushing boundaries in systems biology; Syntopia (France), which develops synthetic biology applications; and Trince from Belgium, innovating in digital laboratory data management.
The energy and enthusiasm circulating Innovation AveNEW at SLAS Europe 2026 are palpable, reflecting a vibrant ecosystem where technological breakthroughs meet commercial strategy. Colin Cook, Co-Founder and CTO of XDemics, and a previous Ignite Award recipient, encapsulated the program’s impact, noting, “There was such an intense buzz on Innovation AveNEW with constant engagement from potential customers, executives, and researchers eager to explore new innovations. The connections forged here are reshaping our business approach and marketing strategy within the high-throughput screening (HTS) space.” His recognition of the Ignite Award as not just an honor but a validation of XDemics’ mission underscores the transformative potential of these ventures, powered by actionable insights and strategic market entry guidance provided by the program.
The momentum generated at Innovation AveNEW speaks to SLAS’s broader mission to amplify multidisciplinary innovation throughout the life sciences community. Vicki Loise, the Chief Executive Officer of SLAS, emphasized this ethos by highlighting the Society’s dedication to supporting startups with critical access to markets, user-driven feedback, and strategic counsel. These elements are essential pillars that empower startups to scale and thrive in an increasingly complex technological landscape. By facilitating this confluence of scientific discovery, technology innovation, and entrepreneurial excellence, SLAS is cementing its role as a catalyst for revolutionary advances in laboratory automation and screening technologies.
The Innovation AveNEW platform stands apart by integrating rigorous scientific scrutiny with entrepreneurial mentorship, providing a scaffold that supports early-stage companies from proof-of-concept through commercialization phases. This integration is crucial in the highly specialized field of laboratory automation, where precision, reproducibility, and scalability dictate success. The program’s emphasis on both technology validation and market alignment ensures participants are not only inventing novel solutions but are also prepared to meet real-world demands and competitive challenges, accelerated by SLAS’s multifaceted promotional and networking infrastructure.
In addition to the exhibition and mentorship benefits, Innovation AveNEW fosters an intellectual exchange through collaborative interactions within the scientific community attending SLAS Europe. Participants engage with a diverse audience, including thought leaders, academic researchers, industrial scientists, and investors, cultivating partnerships that extend beyond the conference floor. This dynamic environment catalyzes knowledge transfer, inspires cross-disciplinary innovation, and often sparks strategic alliances that accelerate product development and adoption cycles.
SLAS Europe 2026 also promises a compelling agenda of sessions, workshops, and keynote addresses focused on the latest trends in life sciences research and technology development. The conference will explore advances in high-resolution imaging, cell culture methodologies, assay development, and laboratory procedure optimization, all of which intersect with the innovations brought forth by the Innovation AveNEW companies. This synergy highlights how the program serves as a microcosm of the broader scientific discourse, bringing fresh perspectives and nascent technologies into the spotlight precisely when they can have the most significant impact.
Moreover, the open access publication avenue through SLAS journals—SLAS Discovery and SLAS Technology—provides a unique platform where Innovation AveNEW participants can disseminate their research results and technological breakthroughs to a global audience. This integration of academic publication with startup promotion ensures the visibility and credibility of emerging technologies, strengthening the evidentiary foundation for adoption while enhancing the scientific rigor behind innovative claims.
As the scientific community prepares for the SLAS Europe 2026 Conference and Exhibition, the anticipation surrounding this year’s Innovation AveNEW cohort is intensifying. These 12 startups exemplify the cutting edge of life sciences innovation, from robotic laboratory automation to synthetic biology, and from systems integration to scalable bioinformatics solutions. Their participation embodies a critical phase in scientific entrepreneurship—transitioning promising ideas into impactful realities that will transform research methodologies and therapeutic discovery paradigms worldwide.
For startups and innovative companies keen to catch this momentum going forward, the SLAS Innovation AveNEW program continues to offer a beacon of opportunity. Registration alerts for SLAS2027 in San Diego and application deadlines for Innovation AveNEW are now open, inviting the next generation of scientific disruptors to join this global community where technology, science, and business converge. Through such dedicated platforms, SLAS is nurturing the future of laboratory automation and screening, driving advances that will ultimately accelerate scientific discovery and improve human health on a global scale.
Subject of Research: Emerging Technologies and Startups in Life Sciences Laboratory Automation and Screening
Article Title: SLAS Europe 2026 Showcases Global Innovation with 12 Selected Startups on the Forefront of Life Sciences Technology
News Publication Date: March 23, 2026
Web References:
– https://8bot-robotics.com/
– https://www.chemetrian.com/
– https://www.culturon.com.au/
– https://www.daltontx.com/
– https://ensynble.com/argo/
– https://linkdlab.de/
– https://lutecedynamics.com/
– https://www.partitionbio.co.uk/
– https://scalables.com/
– https://syncbiosystems.com/
– https://www.syntopia.bio/
– https://trincebio.com/
Keywords: Life sciences, Laboratory automation, Screening technology, Startups, Innovation AveNEW, SLAS Europe 2026, Cell biology, High-throughput screening, Scientific entrepreneurship, Assay development, Biotech startups
